These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7866071)

  • 1. Finding a way through the cost and benefit maze.
    Szczepura A
    BMJ; 1994 Nov; 309(6965):1314-5. PubMed ID: 7866071
    [No Abstract]   [Full Text] [Related]  

  • 2. Study assigns dollar value to alteplase-streptokinase debate.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819
    [No Abstract]   [Full Text] [Related]  

  • 3. Is alteplase (t-PA) more cost-effective than streptokinase?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effective care.
    Greener M
    Health Serv J; 1995 Dec; 105(5483):suppl 5 p.. PubMed ID: 10154611
    [No Abstract]   [Full Text] [Related]  

  • 6. The evidence base for the cost effectiveness of cardiac rehabilitation.
    Taylor R; Kirby B
    Heart; 1997 Jul; 78(1):5-6. PubMed ID: 9290390
    [No Abstract]   [Full Text] [Related]  

  • 7. Interpreting results from thrombolytic megatrials: distinguishing fact from fiction.
    Brophy JM
    Can J Cardiol; 1996 Jan; 12(1):89-92. PubMed ID: 8595575
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost implications of cardiac rehabilitation in older patients.
    Taylor R; Kirby B
    Coron Artery Dis; 1999; 10(1):53-6. PubMed ID: 10196689
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic treatment. Streptokinase is more economical than alteplase.
    Mucklow JC
    BMJ; 1995 Dec; 311(7018):1506. PubMed ID: 8520368
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost of national service frameworks.
    Boyle R
    Hosp Med; 2004 Feb; 65(2):68-9. PubMed ID: 14997769
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
    Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
    Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who uses streptokinase vs alteplase (t-PA), and why?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):428-9. PubMed ID: 10172066
    [No Abstract]   [Full Text] [Related]  

  • 19. On the evidence. Cholesterol and coronary heart disease screening & treatment.
    Turner-Boutle M; Sheldon T; Smith GD; Ebrahim S
    Health Serv J; 1998 Feb; 108(5593):36-7. PubMed ID: 10177607
    [No Abstract]   [Full Text] [Related]  

  • 20. Unintended consequences of applying economic evaluation.
    Oliver A
    J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.